| 08:00-08:30 | Sponsored symposium – Bayer Darolutamide in Prostate Cancer: Bridging Epidemiology and Pivotal trials Evidence Moderator: Zoran Džamić Understanding Prostate Cancer: Epidemiology, Pathophysiology, and the Role of Darolutamide – Zoran Džamić Examining the Evidence: Key Findings from ARAMIS and ARASENS Trials – Suzana Matković |
|
| 08:30-09:00 | Sponsored symposium – Merck Erbitux & Bavencio – journey towards better outcome of oncology treatment Erbitux in the continuum of mCRC treatment– 20 years of heritage – Marija Ristić Bavencio in the treatment of LA/mUC – long term follow up – Lazar Popović Discussion – all participants |
|
| 09:00-09:45 | Scientific session 1 Multidisciplinary treatment of digestive tract malignancies – part 1: Gastric and gastroesophageal cancer Moderators: Marija Ristić, Srđan Nikolić, Suzana Stojanović Rundić |
|
| 09:00-09:20 | Modern systemic treatment of gastric and gastroesophageal cancer | Borislav Belev |
| 09:20-09:35 | Role of radiotherapy in treatment of locally advanced gastric and gastroesophageal cancer | Nikola Milošević |
| 09:35-09:45 | Panel discussion: Zoran Andrić, Dragan Gunjić, speakers | |
| 09:45-10:30 | Sponsored symposium – Amicus Advancing Cancer Care: The Role of Nivolumab and Ipilimumab Ten-Year Outcomes of Nivolumab and Ipilimumab Combination Therapy in Melanoma – Suzana Matković Nivolumab in Urothelial Carcinoma: Clinical Outcomes and Future Directions – Lazar Popović Long-Term Outcomes of Nivolumab and Ipilimumab in Renal Cell Carcinoma: An 8-Year Follow-Up Study – Svetlana Salma Nivolumab in CheckMate 649: A Paradigm Shift in Gastric Cancer Treatment – Marija Ristić |
|
| 10:30-10:45 | Coffee break | |
| 10:45-11:30 | Scientific session 2 Multidisciplinary treatment of digestive tract malignancies – part 2: Hepatocellular carcinoma Moderators: Marija Ristić, Srđan Nikolić, Suzana Stojanović Rundić |
|
| 10:45-11:00 | Locoregional treatments for hepatocellular carcinoma | Sanja Stojanović |
| 11:00-11:15 | Modern treatment algorithm for locally advanced hepatocellular carcinoma | Marija Ristić |
| 11:15-11:30 | Panel discussion: Mlađan Protić, Nenad Mijalković, Saša Jungić, speakers | |
| 11:30-12:30 | Sponsored symposium – ROCHE/Inpharm Navigating the patient journey in HCC treatment: challenges, achievements, and future perspectives Welcome and introduction – Ivan Nikolić The importance of surveillance and diagnosis – Nenad Mijalković What do the results from IMBrave150 reveal to us? – Ivan Nikolić What can we learn from the RWD? – Marija Ristić The impact of innovative therapy on improving treatment outcomes at KBC Zagreb – Borislav Belev Discussion – All participants |
|
| 12:30-12:45 | Coffee break | |
| 12:45-13:30 | Scientific session 3 Multidisciplinary treatment of digestive tract malignancies – part 3: Cholangiocarcinoma Moderators: Marija Ristić, Srđan Nikolić, Suzana Stojanović Rundić |
|
| 12:45-13:00 | NGS in cholangiocarcinoma | Radmila Janković |
| 13:00-13:15 | Systemic treatment of locally advanced cholangiocarcinoma | Marina Marković |
| 13:15-13:30 | Panel discussion: Borislav Belev, Miljana Džunić, Ivan Nikolić, speakers | |
| 13:30-14:00 | Sponsored symposium – Novartis Advancements and Challenges in mCRPC – Comprehensive approaches Moderator: Suzana Matković Speaker: Miloš Veljković |
|
| 14:00-15:00 | Lunch | |
| 15:00-16:15 | Scientific session 4 Scientific projects in Serbia Moderators: Radmila Janković, Ivana Božović Spasojević |
|
| 15:00-15:15 | Twinning to skyrocket scientific excellence towards individual radiosensitivity prediction by raising the bar | Ivana Matić |
| in knowledge transfer, networking, and technological innovation in radiobiology – project: RadExIORSBoost, 101158832 | ||
| 15:15-15:30 | Functional diagnostics in non-small cell lung carcinoma – a new concept for the improvement of personalized therapy in Serbian patients – project: TargetedResponse, 7739737 | Milica Pešić |
| 15:30-15:45 | ADCs in oncology: why “magic bullet” does not mean “magic pharmacology” | Joseph Ciccolini |
| 15:45-16:15 | Discussion | |
| 16:15-18:00 | Scientific session 5 Translational research in radiobiology Moderators: Tatjana Stanojković, Marina Nikitović |
|
| 16:15-16:28 | Biomarkers in radiobiology – challenges and future directions | Nađa Grozdanić Stanisavljević |
| 16:28-16:41 | Molecular Markers for Biological Dosimetry in Radiation Protection, Cancer Risk Assessment and Optimizing Radiotherapy | Igor Belyaev |
| 16:41-16:54 | RILA test in modern clinical practice | Jelena Stanić |
| 16:54-17:07 | The correlation between changes in the levels of IL-6 and TGF-B1 in serum and the occurrence of radiation toxicity in patients with prostate cancer | Katarina Kopčalić |
| 17:07-17:20 | Clinical Trials in Slovakia | Daniela Svetlovska |
| 17:20-17:33 | Different roles of SOX genes in promotion of malignant behavior of glioblastoma cells | Danijela Drakulić |
| 17:33-17:46 | MicroRNA – towards management of glioblastoma | Danijela Stanisavljević Ninković |
| 17:46-18:00 | Discussion | |
| 18:00-18:30 | CLOSING REMARKS & evaluation | |